RESEARCH Open Access

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors

Patrick A Singleton1,2*, Nurbek Mambetsariev1, Frances E Lennon1, Biji Mathew1, Jessica H Siegler1, Liliana Moreno-Vinasco1, Ravi Salgia1, Jonathan Moss2, Joe GN Garcia1

Abstract

Background: Recent cancer therapies include drugs that target both tumor growth and angiogenesis including mammalian target of rapamycin (mTOR) inhibitors. Since mTOR inhibitor therapy is associated with significant side effects, we examined potential agents that can reduce the therapeutic dose.

Methods: Methylnaltrexone (MNTX), a peripheral mu opioid receptor (MOR) antagonist, in combination with the mTOR inhibitors temsirolimus and/or rapamycin, was evaluated for inhibition of VEGF-induced human pulmonary microvascular endothelial cell (EC) proliferation and migration as well as in vivo angiogenesis (mouse Matrigel plug assay).

Results: MNTX inhibited VEGF-induced EC proliferation and migration with an IC50 of ~100 nM. Adding 10 nM MNTX to EC shifted the IC50 of temsirolimus inhibition of VEGF-induced proliferation and migration from ~10 nM to ~1 nM and from ~50 to ~10 nM respectively. We observed similar effects with rapamycin. On a mechanistic level, we observed that MNTX increased EC plasma membrane-associated tyrosine phosphate activity. Inhibition of tyrosine phosphatase activity (3,4-dephostatin) blocked the synergy between MNTX and temsirolimus and increased VEGF-induced tyrosine phosphorylation of Src with enhanced PI3 kinase and mTOR Complex 2-dependent phosphorylation of Akt and subsequent activation of mTOR Complex 1 (rapamycin and temsirolimus target), while silencing Src, Akt or mTOR complex 2 components blocked VEGF-induced angiogenic events.

Conclusions: Our data indicate that MNTX exerts a synergistic effect with rapamycin and temsirolimus on inhibition of VEGF-induced human EC proliferation and migration and in vivo angiogenesis. Therefore, addition of MNTX could potentially lower the dose of mTOR inhibitors which could improve therapeutic index.

Background

Recent therapeutic interventions for the inhibition of cancer progression include drugs that target both tumor growth and angiogenesis. Mammalian target of rapamycin (mTOR) inhibitors, including sirolimus (rapamycin) and temsirolimus, are potential therapeutic agents for hepatocellular cancer and renal cell carcinoma due to their anti-proliferative and anti-angiogenic properties. However, these mTOR inhibitors are often associated with unwanted side effects including rash, asthenia, mucositis, nausea, edema, anemia, hyperglycemia, thrombocytopenia, hyperlipaemia and anorexia [1-5]. Therefore, agents that can reduce the therapeutic concentration of these drugs could have significant clinical utility. We recently demonstrated that mu opioid agonists stimulate VEGF-induced angiogenesis via receptor transactivation and that mu opioid antagonists can inhibit VEGF receptor signaling [6]. During the course of these investigations, we also noted an effect of the peripheral opiate antagonist methylnaltrexone (MNTX) on endothelial cell migration and proliferation that occurred beyond the VEGF receptor, through a mechanism that involves inhibition of Src and Akt. We therefore hypothesized that methylnaltrexone could have synergistic effects with anti-angiogenic drugs (i.e. mTOR inhibitors).

In this study, we demonstrate that methylnaltrexone (MNTX) acts synergistically with the mTOR inhibitors, rapamycin and temsirolimus, on inhibition of VEGF-induced angiogenic events. Specifically, MNTX inhibited EC proliferation with an IC50 of ~100 nM. Adding 10
nM MNTX shifted the IC50 of temsirolimus on EC proliferation from ~10 nM to ~1 nM. Further, adding 10 nM MNTX shifted the IC50 of temsirolimus on inhibition of EC migration from ~50 nM to ~10 nM. The synergistic effects of MNTX and temsirolimus were also demonstrated in an in vivo model of angiogenesis (mouse Matrigel plug assay). There was a shift in the IC50 on inhibition of VEGF-induced EC proliferation and migration with MNTX and rapamycin. The synergistic mechanism involves MNTX activation of tyrosine phosphatase activity with consequent inhibition of VEGF-induced Src activation. MNTX-induced Src inactivation results in inhibition of PI3 kinase and mTOR signaling required for Akt activation (serine/threonine phosphorylation). These results suggest addition of MNTX could potentially lower the therapeutic doses of mTOR inhibitors including rapamycin and temsirolimus.

**Methods**

**Cell Culture and Reagents**

Human pulmonary microvascular EC (HPMVEC) were obtained from Cambrex (Walkersville, MD) and cultured as previously described [7,8] in EBM-2 complete medium (Cambrex) at 37°C in a humidified atmosphere of 5% CO2, 95% air, with passages 6-10 used for experimentation. Unless otherwise specified, reagents were obtained from Sigma (St. Louis, MO). Vascular endothelial growth factor (VEGF) was purchased from R&D Systems (Minneapolis, MN). Methylaltraxone bromide or methylaltraxone (MNTX) was purchased from Malinckrodt Specialty Chemicals (Phillipsburg, NJ). Temsirolimus was acquired through Wyeth Pharmaceuticals. Rapamycin was purchased from Amersham Biosciences (Piscataway, NJ). Methylnaltrexone bromide or methylnaltrexone (MNTX) could potentially lower the therapeutic doses of mTOR inhibitors including rapamycin and temsirolimus.

**Transfection of siRNA against mTOR, Src, Rictor, FKBP12 and Akt**

The siRNA for human mTOR, Src, Rictor, FKBP12 and Akt were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and were utilized according to the manufacturer’s specifications. Briefly, human lung EC were transfected with siRNA using siPORTamine™ as the transfection reagent (Ambion, TX). Cells (~40% confluent) were serum-starved for 1 hour followed by incubated with 250 nM of target siRNA (or scramble siRNA or no siRNA) for 6 hours in serum-free media. The serum-containing media was then added (1% serum final concentration) for 42 h before biochemical experiments and/or functional assays were conducted.

**Human Pulmonary Microvascular EC Migration Assay**

Twenty-four transwell units with 8 μM pore size were used for monitoring in vitro cell migration. HPMVEC (~1 × 10⁴ cells/well) were plated with various treatments (MNTX, temsirolimus, LY294002, 3,4-Dephostatin or siRNA) to the upper chamber and VEGF (100 nM) was added to the lower chamber. Cells were allowed to migrate for 18 hours. Cells from the upper and lower chamber were quantitated using the CellTiter96™ MTS assay (Promega, San Luis Obispo, CA) and read at 492 nm. % migration was defined as the # of cells in the lower chamber % the number of cells in both the upper and lower chamber. Each assay was set up in triplicate, repeated at least five times and analyzed statistically by Student’s t test (with statistical significance set at P < 0.05).

**Human Pulmonary Microvascular EC Proliferation Assay**

For measuring cell growth, HPMVEC [5 × 10³ cells/well pretreated with various agents (MNTX, temsirolimus, LY294002, 3,4-Dephostatin or siRNA) were incubated with 0.2 ml of serum-free media containing 100 nM VEGF for 24 h at 37°C in 5%CO2/95% air in 96-well culture plates. The in vitro cell proliferation assay was analyzed by measuring increases in cell number using the CellTiter96™ MTS assay (Promega, San Luis Obispo, CA) and read at 492 nm. Each assay was set up in
triplicate, repeated at least five times and analyzed statistically by Student’s t test (with statistical significance set at \( P < 0.05 \)).

Tyrosine Phosphatase Assay
HLMVEC were treated with MNTX (100 nM), VEGF (100 nM) and/or morphine (100 nM) for 5 minutes. Lysates were then obtained and further purified to enrich plasma membrane-associated proteins by wheat germ agglutinin (WGA) affinity as previously described [9] and analyzed for tyrosine phosphatase activity using the fluorometric Rediplate™ 96 EnzChek Tyrosine Phosphatase Assay Kit (Invitrogen (Molecular Probes), Eugene, OR) as we have previously described [10]. Briefly, cellular materials are incubated in reaction buffer at 30°C and then added to a 96 well plate coated with 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP). Tyrosine phosphatase activity cleaves DiFMUP into DiFMU with an excitation/emission maxima of 358/452 nm.

In Vivo Angiogenesis Assay
The Matrigel plug assay was used to assess in vivo angiogenesis [11]. 10-week-old female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were injected subcutaneously on the ventral abdomen with 500 μl Matrigel (BD Biosciences, San Jose, CA) containing either MNTX (100 nM), temsirolimus (10 nM), or both drugs (100 nM MNTX and 10 nM temsirolimus). 20 ng VEGF was added to all Matrigel plugs. After 21 days, the plugs were removed and analyzed for hemoglobin content. The plugs were weighed and homogenized, and their hemoglobin content was quantified using the QuantiChrom™ hemoglobin assay kit (BioAssay Systems, Hayward, CA).

Results
Analysis of methylnaltrexone (MNTX) synergy with mTOR inhibitors on inhibition of human endothelial cell (EC) proliferation and migration
Given our previous published data indicating that MNTX inhibits VEGF-induced Akt activation [10], we hypothesized that MNTX could have synergistic effects with anti-angiogenic drugs that regulate Akt signaling including mTOR inhibitors. Figure 1-A indicates that MNTX inhibits EC proliferation with an IC50 of ~100 nM. Adding ten fold lower concentration of MNTX (10 nM) to human EC shifted the IC50 of temsirolimus from ~10 nM to ~1 nM. These results were further confirmed with isobologram analysis [12] (Figure 1-B). Adding 10 nM MNTX shifted the IC50 of temsirolimus on inhibition of EC migration from ~50 nM to ~10 nM (Figure 1-C) and the synergy was confirmed using isobologram analysis [12] (Figure 1-D). These synergistic effects were not observed with the uncharged mu opioid antagonist, naltrexone (Figure 2-A, B; Figure 3-A, B). The synergistic effects of MNTX were paralleled with the mTOR inhibitor, rapamycin (see Additional Figure 1).

The roles of mTOR Complex components, Akt and Src in MNTX and temsirolimus inhibition of VEGF-induced angiogenesis
We next examined the mechanism(s) of the synergistic effects of MNTX with temsirolimus on inhibition of VEGF-induced angiogenic events. Our previous published data indicate that Akt activation is important in VEGF-induced angiogenesis [10]. Akt is activated by threonine phosphorylation (T308) in the catalytic domain by PI3 kinase-dependent PDK-1 and by serine phosphorylation (S473) in the hydrophobic motif by various kinases including mTOR [13-15]. The substrate specificity of mTOR is regulated by complex formation with other proteins. Specifically, mTOR exists in a rapamycin-sensitive complex (mTOR Complex 1) with the regulatory-associated protein of mTOR (Raptor) and a rapamycin-insensitive complex (mTOR Complex 2) with the rapamycin-insensitive companion of mTOR, Rictor [1-5,13,15]. We silenced (siRNA) selective proteins in human EC including mTOR (Figure 4-A). Pre-treating human EC with MNTX, temsirolimus or mTOR siRNA followed by VEGF challenge revealed that Akt activation (serine/threonine phosphorylation) is blocked by MNTX. Further, silencing mTOR blocked VEGF-induced serine, but not threonine Akt phosphorylation. Interestingly, the mTOR inhibitor, temsirolimus, did not attenuate Akt activation but inhibited the mTOR Complex 1 target p70 S6K [4] (Figure 4-B).

To further investigate the roles of MNTX and temsirolimus in VEGF-mediated Akt signaling, we examined two main mTOR-associated protein complexes, mTOR Complex 1, consisting of various proteins including mTOR, FKBP12 (a major target of mTOR inhibitors including temsirolimus) and Raptor, and mTOR Complex 2, consisting of various proteins including SIN1 and Rictor. Immunoprecipitation with either Rictor or Raptor antibody after VEGF treatment of human EC with MNTX or temsirolimus pre-treatment indicated that VEGF induces mTOR Complex 1 and mTOR Complex 2 formation. Both MNTX and temsirolimus block mTOR Complex 1 formation while only MNTX blocks mTOR Complex 2 formation (Figure 5-A).

We and others have previously published that VEGF induces Src and PI3 kinase activation in human EC [6,16,17]. We inhibited PI3 kinase activity with LY294002 or silenced (siRNA) Src or Rictor (required for mTOR Complex 2 formation), challenged EC with VEGF and examined Akt activation. Our results (Figure 5-B) indicate that Src is required for both serine and threonine
The phosphorylation of Akt, the PI3 kinase pathway is required for threonine phosphorylation of Akt and mTOR Complex 2 is required for serine phosphorylation of Akt.

Similar to our results in Figures 4 and 5, we observed that silencing (siRNA) of mTOR, Akt, Src, Rictor or inhibition of PI3 kinase activity significantly attenuated VEGF-induced human EC proliferation (Figure 6-A) and migration (Figure 6-B) with Src silencing inducing the greatest inhibition of these activities. In addition, silencing Src or FKBP12 (direct target of temsirolimus [2,3,5]) blocked the synergy observed with MNTX and temsirolimus on VEGF-induced EC proliferation (Figure 6-C) and migration (Figure 6-D). However, our synergism analysis is complicated by the potent effects of Src and FKBP12 silencing alone.

The role of tyrosine phosphatase activity in MNTX and temsirolimus inhibition of VEGF-mediated angiogenesis

Our previous studies indicate that MNTX attenuates VEGF-induced pp60 Src activation (tyrosine phosphorylation) [6,10]. One possible mechanism of attenuating Src tyrosine phosphorylation is through tyrosine phosphatase activity [18,19]. To investigate this, we measured EC plasma membrane-associated tyrosine phosphatase activity and discovered that VEGF and morphine inhibit,
while MNTX promotes tyrosine phosphatase activity (Figure 7-A). Treated of human EC with the potent tyr-
osine phosphatase inhibitor, 3.4-dephostatin [20] blocked MNTX inhibition of VEGF-induced Src and Akt activation (Figure 7-B) and reversed MNTX syner-
gistic effects with temsirolimus on VEGF-induced prolif-
eration (shift in the IC50 from ~1 nM to ~20 nM, Figure 7-C) and VEGF-induced migration (shift in the IC50 from ~5 nM to ~70 nM, Figure 7-D).

**In vivo analysis of MNTX synergy with temsirolimus on inhibition of angiogenesis**

Considering the results of our in vitro human EC stu-
dies, we next examined the role of MNTX and temsirolimus on angiogenesis in vivo. In the mouse Matrigel plug assay [11], addition of 100 nM MNTX inhibited angiogenesis (Figure 8). Importantly, addition of MNTX in combination with temsirolimus inhibited angiogenesis to a greater extent than either drug alone (Figure 8). These results indicate MNTX and temsirolimus have a synergistic effect on inhibition of angiogen-
sis in vivo.

**Discussion**

We and others have previously noted an effect of opi-
ates on endothelial cell migration and proliferation, and an effect of opiate antagonists in attenuating opiate induced angiogenesis [6,8,10]. The selective peripheral
antagonist of the mu opioid receptor, MNTX, administered subcutaneously, is approved in the USA, EU, Canada and Australia. In the USA, it is indicated for the treatment of opioid-induced constipation in patients with advanced illness (i.e. cancer, AIDS) who are receiving palliative care, when responses to laxatives have not been sufficient [21-24]. Use in attenuating other side effects of opiates has been studied [25]. In this study, we present the novel findings that MNTX acts in a synergistic manner with the mTOR inhibitors, rapamycin and temsirolimus, in inhibiting VEGF-induced angiogenic events. Our results indicate that the synergistic effects of MNTX with mTOR inhibitors are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway. MNTX inhibits the mu opioid receptor and stimulates tyrosine phosphatase activity which inhibits VEGF-induced Src activation and Src-regulated PI3 kinase and mTOR Complex 2-mediated Akt activation. Temsirolimus and rapamycin inhibit the downstream target of activated Akt, mTOR.

Figure 3 Isobologram analysis indicating a lack of synergy of naltrexone with temsirolimus on VEGF-induced human EC proliferation and migration. Panel A: Isobologram analysis of the combination of naltrexone and temsirolimus on inhibition of VEGF-induced proliferation. The dashed line indicates a zero interaction for the isobole. The close proximity of the data with the dashed line indicates there is not a synergistic interaction. Panel B: Isobologram analysis of the combination of naltrexone and temsirolimus on inhibition of VEGF-induced migration. The dashed line indicates a zero interaction for the isobole. The close proximity of the data with the dashed line indicates there is not a synergistic interaction.
Complex 1 [1,15,26]. Inhibition of these events promotes synergistic inhibition of VEGF-induced angiogenesis (Figure 9). Therefore, we hypothesize that, in addition to its effects on GI motility, MNTX might have clinical utility by potentially lowering the therapeutic doses of mTOR inhibitors in the treatment of various diseases requiring angiogenesis including cancer.

We have focused our studies on methylnaltrexone (MNTX) because it is more likely to be used in advanced illness clinical settings than tertiary mu opioid antagonists. Uncharged mu opioid antagonists, including naloxone and naltrexone, are fairly lipid soluble and cross the blood-brain barrier easily [27-29]. Despite numerous attempts at regulating doses, mu opioid antagonists have proven unsuitable for patients receiving opiates for pain management because of analgesia reversal and breakthrough pain [30]. MNTX is a quaternary derivative of the tertiary mu opiate antagonist naltrexone [31]. The addition of the methyl group to naltrexone at the amine in the ring forms the compound N-methylnaltrexone with greater polarity and lower lipid solubility. Because MNTX does not cross the blood-brain barrier, it could play a therapeutic role in reversing the peripheral effects of opiates in palliative

---

**Figure 4 Analysis of MNTX, temsirolimus and mTOR regulation of VEGF-induced Akt activation in human EC.** Panel A: Human EC were either untreated (control) or treated with scramble siRNA, mTOR siRNA, Src siRNA, Rictor siRNA or Akt siRNA for 48 hours, lysates obtained, run on SDS-PAGE and immunoblotted with anti-mTOR (a), anti-Src (b), anti-Rictor (c), anti-Akt (d) or anti-actin (e) antibody. Panel B: Human EC were serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without pretreatment (1 hour) with 100 nM MNTX, 100 nM temsirolimus, or pretreatment for 48 hours with mTOR siRNA. EC lysates were obtained, run on SDS-PAGE and immunoblotted with anti-pSer473Akt (a), anti-pThr308Akt (b), anti-AKT (c), anti-pThr389 p70 S6K (d) or anti-p70 S6K (e) antibody.
Figure 5 Determination of mTOR Complex 1 and mTOR Complex 2 regulation of VEGF-induced Akt activation in human EC. Panel A
Human EC were serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without pretreatment (1 hour) with 100 nM MNTX or 100 nM temsirolimus. EC were then solubilized in IP buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 20 mM MgCl₂, 1% Nonidet P-40 (NP-40), 0.2 mM phenylmethylsulfonyl fluoride, 1:250 dilution of Calbiochem protease inhibitor mixture 3) and immunoprecipitated with either anti-Raptor (mTOR Complex 1 component) or anti-Rictor (mTOR Complex 2 component) antibody. The immunoprecipitated material was run on SDS-PAGE and immunoblotted with anti-mTOR (a, d), anti-FKBP12 (mTOR Complex 1 component and direct target of temsirolimus) (b), anti-Raptor (c), anti-SIN1 (mTOR Complex 2 component) (e) or anti-Rictor (f) antibody.

Panel B: Human EC were serum starved for one hour and either untreated (control) or treated with VEGF (100 nM, 5 minutes) with or without pretreatment (1 hour) with LY294002 (PI3 kinase inhibitor, 10 μM) or pretreated for 48 hours with Src or Rictor (mTOR Complex 2 component) siRNA. EC lysates were obtained, run on SDS-PAGE and immunoblotted with anti-pSer⁴⁷³Akt (a), anti-pThr³⁰⁸Akt (b), or anti-AKT (c) antibody.
Figure 6 The effects of mTOR, Akt, Src, Rictor and PI3 kinase on VEGF-induced human EC proliferation and migration. Panel A: Bar graph representation of human EC assayed for VEGF (100 nM)-induced proliferation (24 hours) in the presence or absence of 48 hour pretreatment with mTOR siRNA, Akt siRNA, Src siRNA, Rictor (mTOR Complex 2 component) siRNA or pretreatment (1 hour) with LY294002 (PI3 kinase inhibitor, 10 μM). Experiments were performed in triplicate. Error bars = standard deviation. Panel B: Bar graph representation of human EC assayed for VEGF (100 nM)-induced migration (24 hours) in the presence or absence of 48 hour pretreatment with mTOR siRNA, Akt siRNA, Src siRNA, Rictor (mTOR Complex 2 component) siRNA or pretreatment (1 hour) with LY294002 (PI3 kinase inhibitor, 10 μM). Experiments were performed in triplicate. Error bars = standard deviation. Panel C: Bar graph representation of human EC assayed for VEGF (100 nM)-induced proliferation (24 hours) in the presence or absence of 48 hour pretreatment with Src or FKBP12 siRNA with addition of 100 nM MNTX and/or 10 nM temsirolimus. Experiments were performed in triplicate. Error bars = standard deviation. Panel D: Bar graph representation of human EC assayed for VEGF (100 nM)-induced migration (24 hours) in the presence or absence of 48 hour pretreatment with Src or FKBP12 siRNA with addition of 100 nM MNTX and/or 10 nM temsirolimus. Experiments were performed in triplicate. Error bars = standard deviation.
Figure 7 3,4-Dephostatin inhibition of tyrosine phosphatase activity blocks MNTX synergistic effects with temsirolimus on inhibition of VEGF-induced angiogenic events. 

Panel A: Bar graph representation of human EC plasma membrane-associated tyrosine phosphatase activity (see Methods) with VEGF (100 nM), morphine (100 nM), MNTX (100 nM) or combination treatment. The asterisks indicate a statistically significant difference (p < 0.05) between control and drug challenge. In addition, there is a statistically significant difference (p, 0.05) between without MNTX and with MNTX treatment.

Panel B: Bar graph representation of the ratio of phospho-protein to total protein using immunoblot analyses of pSer473Akt, pThr308Akt and pTyr418Src of human EC treated with 100 nM VEGF with or without 10 nM or 100 nM MNTX in the presence or absence of the tyrosine phosphatase inhibitor, 3,4-dephostatin (50 μM). Experiments were performed in triplicate. Error bars = standard deviation.

Panel C: Graphical representation of the 50% inhibition concentration (IC50, nM) of human EC assayed for VEGF (100 nM)-induced proliferation (24 hours) of temsirolimus with or without 10 nM MNTX in the presence or absence of the tyrosine phosphatase inhibitor, 3,4-dephostatin (50 μM). Experiments were performed in triplicate. Error bars = standard deviation.

Panel D: Graphical representation of the 50% inhibition concentration (IC50, nM) of human EC assayed for VEGF (100 nM)-induced migration (24 hours) of temsirolimus with or without 10 nM MNTX in the presence or absence of the tyrosine phosphatase inhibitor, 3,4-dephostatin (50 μM). Experiments were performed in triplicate. Error bars = standard deviation.
Figure 8  In vivo analysis of MNTX synergy with temsirolimus on inhibition of angiogenesis. In Panels A and B, 10-week-old female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were injected subcutaneously on the ventral abdomen with 500 μl Matrigel (BD Biosciences, San Jose, CA) containing either MNTX (100 nM), temsirolimus (10 nM), or both drugs (100 nM MNTX and 10 nM temsirolimus). 20 ng VEGF was added to all Matrigel plugs. After 21 days, the plugs were removed. **Panel A**: Pictures of Matrigel plugs after removal from mice. **Panel B**: Graphical analysis of Matrigel plug hemoglobin content. The plugs were weighed and homogenized, and their hemoglobin content was quantified using the QuantiChrom™ hemoglobin assay kit (BioAssay Systems, Hayward, CA), n = 3 per group. The asterisks indicate a statistically significant difference (p < 0.05) between treatment and control. There is also a statistically significant difference (p < 0.05) between MNTX or temsirolimus treatment alone versus in combination.
care, especially for patients taking high doses of opiates for analgesia [32-37]. The plasma concentrations of morphine and MNTX in patients after parenteral or oral administration are consistent with the levels that regulated synergistic inhibition of VEGF-induced angiogenesis and inhibited Src in our in vitro model (IC50 = ~10 nM) [10].

We focused our studies on temsirolimus and rapamycin based on our previous published data that MNTX regulates VEGF-induced Akt activation [10] and the intricate relationship between Akt and mTOR pathways [5,26]. Both rapamycin and temsirolimus, a soluble ester analog of rapamycin, exert their action by binding to the intracellular protein, FKBP12, and inhibiting mTOR Complex 1 formation [38-40]. However, mTOR can still complex with SIN1 and Rictor (mTOR Complex 2) [1,15,26]. The mTOR Complex 2 serine phosphorylates Akt and is involved in actin cytoskeletal regulation [2,4,14,41,42]. Akt can also be threonine phosphorylated by PI3 kinase activation of PDK1 [41-45]. Activated (serine/threonine phosphorylated) Akt promotes mTOR Complex 1 assembly through inactivation (phosphorylation) of TSC2 and PRAS40 [5,26]. Activated mTOR Complex 1 phosphorylates several target proteins.

Figure 9 Schematic diagram of a proposed mechanism of MNTX synergistic effects with temsirolimus on inhibition of VEGF-induced angiogenic events. VEGF binding to VEGF receptors (1) induces Src activation (tyrosine phosphorylation)(2), Src-mediated PI3 kinase/PDK1 activation with consequent phospho-threonine Akt phosphorylation (3) and mTOR Complex 2 formation (mTOR/SIN1/Rictor) with consequent phospho-serine Akt phosphorylation (4). Activated (serine/threonine phosphorylated) Akt promotes mTOR Complex 1 formation (mTOR/FKBP12/Raptor) (5) required for EC proliferation and migration (6). MNTX inhibits the mu opioid receptor and promotes tyrosine phosphatase activity and Src inactivation (7). Temsirolimus binds to FKBP12 and inhibits mTOR Complex 2 formation (8). Therefore, the synergistic effects of MNTX with temsirolimus are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway. MNTX can have important clinical utility by potentially lower the therapeutic dose of temsirolimus in the treatment of various diseases requiring angiogenesis including cancer.
including S6K and 4EBP1 involved in cell proliferation, growth and survival [1,2,4,5,26].

The effects of MNTX on inhibition of mTOR described in this manuscript go beyond VEGF receptor activation and extend to downstream signaling pathways. We and others have previously reported that inhibition of Src protects from EC barrier disruption and angiogenesis [6,8,10]. Src regulates several potential angiogenic events including EC contraction and vascular permeability [43,44]. We extended these findings by observing that Src regulates VEGF-induced, PI3 kinase and mTOR-dependent, serine/threonine phosphorylation of Akt important for EC proliferation and migration. Further, Src regulates the synergistic effects of MNTX with temsirolimus on inhibition of VEGF-induced angiogenic events. We have previously demonstrated that MNTX increases tyrosine phosphatase activity, including RPTPμ [10]. This study extends these findings by demonstrating that the potent protein tyrosine phosphatase inhibitor, 3,4-Dephostatin, blocks MNTX inhibition of VEGF-induced Src and Akt phosphorylation. 3,4-Dephostatin is known to block the phosphatase activity of PTP-1B, SHPTP-1 and CD45 [20,40,46-48]. In addition, 3,4-Dephostatin increased insulin-induced tyrosine phosphorylation of PLCγ2, c-Cbl and the regulatory subunit of PI3 kinase (a known Src substrate) [48]. We are currently examining the role of these tyrosine phosphatases in MNTX inhibition of VEGF-induced Src activation and angiogenesis.

Temsirolimus was approved by the FDA in 2007 for the treatment of advanced renal cell carcinoma, a disease resistant to existing chemotherapies (IFN-α, IL-2) [3,38-40]. There have been other attempts to potentiate the action of temsirolimus. In Phase 3 clinical trials, temsirolimus, IFN-α or temsirolimus + IFN-α treatment resulted in median survival rates of 10.9 months, 7.3 months and 8.4 months, respectively [3,38-40]. IFN-α did not augment temsirolimus treatment alone [3,38-40]. The results of these clinical trials indicate the need for an effective drug in temsirolimus combination therapy. Our observations that MNTX acts synergistically with mTOR inhibitors on inhibition of VEGF-induced angiogenic events merit clinical studies.

Conclusions

Our results indicate that MNTX exerts a synergistic effect with rapamycin and temsirolimus on inhibition of VEGF-induced human EC proliferation and migration and in vivo angiogenesis. These synergistic effects are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway. MNTX inhibits the mu opioid receptor and stimulates tyrosine phosphatase activity which inhibits VEGF-induced Src activation and Src-regulated PI3 kinase and mTOR Complex 2-mediated Akt activation. Temsirolimus and rapamycin inhibit the downstream target of activated Akt, mTOR Complex 1. Inhibition of these events promotes synergistic inhibition of VEGF-induced angiogenesis (Figure 9). Therefore, addition of MNTX could potentially lower the dose of mTOR inhibitors which could improve therapeutic index.

Additional file 1: Determination of methylnaltrexone (MNTX) synergistic effects with rapamycin on inhibition of VEGF-induced human endothelial cell (EC) proliferation and migration. This file shows through inhibition curves and isobologram analysis that MNTX acts synergistically with the mTOR inhibitor, rapamycin, on inhibition of VEGF-induced angiogenic events. Click here for file [http://www.biomedcentral.com/content/supplementary/2040-2384-2-5-S1.PDF]
regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006, 281:34381-93.

8. Singleton PA, Moreno-Vinaco L, Sammann S, Wanderling SL, Moss J, Garcia JGN. Attenuation of Vascular Permeability by Methylnaltrexone: Role of MOP-R and SP3 Transactivation. Am J Respir Cell Mol Biol 2007, 37:222-31.

9. Wang Y, Ao X, Xuong H, Konanur M, Miller FR, Goodison S, Lubman DM. Membrane Glycoproteins Associated with Breast Tumor Cell Progression Identified by a Lectin Affinity Approach. J Proteome Res 2008, 7:4313-4325.

10. Singleton PA, Garcia JGN, Moss J. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008, 7:1669-79.

11. Liu Z, Kobayashi K, van Dinther M, van Heiningen SH, Valdimardottir G, van Laar T, Scharpfeniecker M, Lovik CW, Goumans MJ, Ten Dijke P, Pardalí E. VEGF and inhibitors of TGFBeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J Cell Sci 2009, 122:3904-32.

12. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001, 289:865-72.

13. Utson TO. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) 2007, 20:24-8.

14. Jacinto E, Lovett-Krug R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-8.

15. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Sabatini DM, Hsp90 in response to vascular endothelial growth factor (VEGF) is a rapamycin insensitive and raptor-independent pathway that regulates Tempst P, Sabatini DM: A rapamycin insensitive. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-8.

16. Duval M, Le Boeuf F, Huot J, Gratton JP. Rector, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-302.

17. Dufau M, Le Bosuf F, Huot J, Grattin JP. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Cell Biol 2007, 18:4659-68.

18. Dawson NS, Zavejka DC, Wu MH, Granger HJ. Signaling pathways mediating VEGF165-induced calcium transients and membrane depolarization in human endothelial cells. Faschi J 2006, 20:991-3.

19. den Hertog J, Grooten A, Wijk van der T. Redox regulation of protein-tyrosine phosphatases. Arch Biochem Biophys 2005, 434:11-5.

20. Stoker AW. Protein tyrosine phosphatases and signalling. J Endocrinol 2005, 185:19-33.

21. Umezawa K, Kawakami M, Watanabe T. Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. Pharmacol Ther 2003, 99:15-24.

22. Slättkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Singleton DHJ, Stephenson R, Portenoy R, Stambler N, Israel R. Methylnaltrexone for opioid-induced constipation: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008, 35:458-68.

23. Methylnaltrexone & Registler. Methylnaltrexone for opioid induced constipation. Med Lett Drugs Ther 2008, 50:63-4.

24. Moss J, Rosow CE. Development of peripheral opioid antagonists: new insights into opioid effects. Mayo Clin Proc 2008, 83:1116-80.

25. Garcia JA. Danielpout. D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7:1347-54.

26. Moss J, Foss J. Pain relief without side effects: Peripheral Opiate Antagonists. Philadelphia: Lipincott Williams & Wilkins 2005.

27. Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991, 41:526-44.

28. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehavin-Hudkins DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004, 16(Suppl 2):46-53.

29. Sykes NP. Using Oral Naloxone in Management of Opioid Bowel Dysfunction. New York: Haworth Medical Press 2005.

30. Yuan CS, Foss JF, O’Connor M, Osinski J, Karrion T, Moss J, Roizen MF. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000, 283:867-72.

31. Stanski DR, Greenblatt DJ, Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 1978, 24:52-9.

32. Neumann PB, Henrikson H, Grosman N, Christensen CB. Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 1982, 13:247-52.

33. Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998, 16:388-402.

34. Yuan CS, Doshi H, Chamey MR, O’Connor M, Karrison T, Malecka S, Israel RI, Moss J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005, 45:538-46.

35. Cannom RR, Mason RJ. Methylnaltrexone: the answer to opioid-induced constipation?. Expert Opin Pharmacother 2009, 10:1039-45.

36. Lausten G, Camillo F, Johnson J, Smith C. Drug approvals: ‘08 in review. Methylnaltrexone (Relistor). Nurse Pract 2009, 34:31.

37. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther 2009, 26:35-67.

38. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Stoszewska E, Osman J, McDermott D, Bodrogil J, Kovacevic Z, Lesovsky V, Schmidt-Wolf IG, Barbaros O, Okmen E, D’Oste T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2009, 356:2271-81.

39. Figlin RA. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008, 5:601-9.

40. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-7.4.

41. Frost RA, Lang CH: Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 2007, 103:378-87.

42. Mucha DR, Myers CL, Schaeffer RC Jr. Endothelial contraction and monolayer hyperpermeability are regulated by Src kinase. Am J Physiol Heart Circ Physiol 2003, 284:H994-H1002.

43. Weis S, Cui J, Barnes L, Chern E. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004, 167:223-9.

44. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001, 276:31588-62.

45. Liu G. Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. Curr Med Chem 2003, 10:1407-21.

46. Kakeya H, Imoto M, Takahashi Y, Naganawa H, Takeuchi T, Umezawa K, Drophostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. J Structure determination. J Antibiot (Tokyo) 1993, 46:1716-9.

47. Suzuki T, Hiroki A, Watanabe T, Yamashita T, Takei I, Umezawa K. Drophostatin, a novel protein tyrosine phosphatase inhibitor, B-3,4-drohostatin, on culture 3T3-L1 adipocytes. J Biol Chem 2001, 276:27351-8.

http://www.jangiogenesis.com/content/2/1/5

Cite this article as: Singleton et al.: Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors. Journal of Angiogenesis Research 2010 2:5.